Author Archives: Megan Thomas

#AI #AI / data analytics / healthtech / informatics #Big pharma #Drug development #Drug discovery #GlobalData

AI and big data will continue to disrupt pharmaceutical sector, says research

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey… Read More

#Market Reports #News #Trending News #Trends & Analysis

#Animal testing #Biopharmaceuticals #R&D #Research

ABPI responds to new UK animal R&D statistics

The UK government has released a national statistics report, “Annual Statistics of Scientific Procedures on Living Animals, Great Britain, 2020”. In summary, 2.88 million procedures were carried out in Great Britain involving living animals in 2020. Key results of the report include the fact that the 2.88 million procedures in… Read More

#News #Trending News

#Bioscience #Biotechnology #Cell and gene therapy #Cell and Gene Therapy Catapult #Drug development #Life sciences #Research

GSK unveils plan for one of Europe’s largest life science campuses

GSK has announced that it planning to develop its research & development site in Stevenage, UK,  into one of Europe’s largest clusters for biotechnology and early-stage life science companies. The concept has been developed in partnership with Stevenage Bioscience Catalyst (SBC), among others and would build on GSK’s existing presence,… Read More

#News

#Biopharmaceuticals #Biotechnology #Drug development #Investment #Pharmaceuticals #Therapeutics

New laboratory boosts high-potency drug development

US-based Continuus Pharmaceuticals has opened a new laboratory space and new technology to help the development of high-potency drugs. The new lab and technology are the latest developments in Continuus’ ongoing expansion, coming six months after receiving a US$69.3 million US government contract for the domestic production of medicines. “Our… Read More

#News

#Covid-19 #Investment #Life sciences #Public health #Social enterprise

Mologic becomes a ‘social enterprise’ following acquisition

A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, has launched Global Access Health (GAH), a social enterprise that aims to expand access to affordable medical technology. The group has financed the acquisition of Mologic,… Read More

#News

#AI / data analytics / healthtech / informatics #Genomics #Public health

AWS for Health: accelerating innovation through data access

Dotmatics has announced its support of the AWS for Health initiative from Amazon Web Services (AWS), which aims to improve laboratory efficiency and accelerate the pace of scientific innovation by facilitating more rapid data access, analysis and exchange between scientists worldwide. AWS for Health is an initiative featuring services and… Read More

#News

#Automated workflows #Biotechnology #Life sciences #Research #Webinar

Multimodal zebrafish workflows on a confocal imaging reader: webinar

Join this BioTek webinar to learn how quantitative phenotypic analysis is central to many zebrafish research workflows. Phenotypic analysis often involves leveraging multiple technologies for molecular, cellular and organismal-level evaluations. Accordin to Biotek, the new Cytation C10 confocal imaging reader is a powerful single-instrument solution for multimodal plate reading,… Read More

#News

#CAR-T #Cell therapy

Bioelectronic assays: Setting a standard for potency measurement

Bioelectronic assays allow scientists to precisely and continuously monitor cultured cells without labels or dyes. Dr Jim Ross, Chief Technology Officer and co-founder of Axion Biosystems, elaborates. Young industry, massive momentum Although cell-based immunotherapies for cancer treatment are relatively new, they are poised to take the biomedical world by storm. Read More

#Exclusive Content #News

#Covid-19 #Genomics #Infectious diseases #Therapeutics

Genomics analysis on why Covid-19 affects people so differently

Last year scientists from around the world undertook genetic analysis to uncover the genetic factors influencing why some Covid-19 patients develop severe, life-threatening disease requiring hospitalisation, while others escape with mild symptoms or none at all. A comprehensive summary of their findings to date, published in Nature, reveals 13 loci,… Read More

#Covid-19 #News #Trending News

#Biotherapeutics #Clinical research #Microbiome #Therapeutics

Report reveals the potential of microbiome-targeting therapeutics

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is… Read More

#Market Reports #News #Trends & Analysis

#Biotherapeutics #Clinical trial #Clinical Trial Authorisation #Drug delivery #Drug development #Therapeutics

FDA Fast Track designation for Parkinson’s Disease treatment

BlueRock Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase I study. “Receiving Fast Track Designation from the FDA is an important step,… Read More

#News

#3D modelling #Clinical trials #Drug development #Drug discovery

Lonza and CN Bio hepatocyte distribution agreement

Lonza and CN Bio have entered into a distribution agreement where Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in its PhysioMimix Single-and Multi-Organ MPS. The aim is to change the way human-relevant pre-clinical data is generated. With prequalified cells, customers can… Read More

#News

#Biotechnology #DNA #Drug development #Drug discovery

Pioneering DNA-encoded chemical library technology

As an expert in DNA-encoded chemical library (DEL) technology, X-Chem has set up a free-to-register, interactive virtual booth to display how it efficiently unlocks possibilities in small molecule drug discovery and development. The booth includes information about X-Chem, a video library, brochures and insert sheets on mechanical chemistry,… Read More

#News

#Covid-19 #Life sciences #Synthetic chemistry

£54 million project benefits pre-clinical discovery CRO

Loughborough’s life sciences hub Charnwood Campus in the UK has recommissioned its synthetic and chemistry research facility to cater to the needs of pre-clinical discovery contract research organisation (CRO) Charnwood Molecular. It will cost £54 million. The new laboratories will provide capacity for future growth and expansion of Charnwood Molecular’s medicinal chemistry… Read More

#News

#Cannabinoid #Drug design #Drug discovery #Medicinal cannabis #Pharma

Cultivating cannabis for pharmaceuticals: an inside view

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to… Read More

#Business & Investment #Editor's Choice #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News